These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 11786674)

  • 1. Potential mechanisms of action of superselective alpha(1)-adrenoceptor antagonists.
    Price D
    Eur Urol; 2001; 40 Suppl 4():5-11. PubMed ID: 11786674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Storage and voiding symptoms: pathophysiologic aspects.
    Andersson KE
    Urology; 2003 Nov; 62(5 Suppl 2):3-10. PubMed ID: 14662401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial choices and final outcomes in lower urinary tract symptoms.
    Speakman MJ
    Eur Urol; 2001; 40 Suppl 4():21-30. PubMed ID: 11786676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of isocorynoxeine, from Uncaria, on lower urinary tract dysfunction caused by benign prostatic hyperplasia via antagonism of α
    Li T; Xu K; He J; Jahan N; Song J; Wang S
    Toxicol Appl Pharmacol; 2019 Aug; 376():95-106. PubMed ID: 31145917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system.
    Andersson KE; Gratzke C
    Nat Clin Pract Urol; 2007 Jul; 4(7):368-78. PubMed ID: 17615548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life.
    Djavan B
    Urology; 2003 Sep; 62(3 Suppl 1):6-14. PubMed ID: 12957195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
    Nickel JC
    Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relation between expression of α(1)-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms.
    Kurizaki Y; Ishizuka O; Imamura T; Ichino M; Ogawa T; Igawa Y; Nishizawa O; Andersson KE
    Scand J Urol Nephrol; 2011 Feb; 45(1):15-9. PubMed ID: 20961266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies.
    Kenny BA; Miller AM; Williamson IJ; O'Connell J; Chalmers DH; Naylor AM
    Br J Pharmacol; 1996 Jun; 118(4):871-8. PubMed ID: 8799556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. alpha1-adrenoceptors and bladder function.
    Andersson K
    Eur Urol; 1999; 36 Suppl 1():96-102. PubMed ID: 10393481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
    Andersson KE
    Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications.
    O'Leary MP
    Urology; 2003 Sep; 62(3 Suppl 1):15-23. PubMed ID: 12957196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders.
    Nomiya M; Yamaguchi O
    J Urol; 2003 Aug; 170(2 Pt 1):649-53. PubMed ID: 12853849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.
    Dunn CJ; Matheson A; Faulds DM
    Drugs Aging; 2002; 19(2):135-61. PubMed ID: 11950378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do we know everything about alpha-blockade in the management of lower urinary tract symptoms?
    Puppo P
    Eur Urol; 2001 Jan; 39 Suppl 2():38-41. PubMed ID: 11223696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate growth inhibition by subtype-selective alpha(1)-adrenoceptor antagonist naftopidil in benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Oda N; Koshimizu TA; Hayashi Y; Kiniwa M; Tsujimoto G; Kohri K
    Prostate; 2009 Oct; 69(14):1521-8. PubMed ID: 19544328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment.
    Schulman CC
    Urology; 2003 Sep; 62(3 Suppl 1):24-33. PubMed ID: 12957197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Categorization of adrenergic alpha 1 receptors in detrusor of patients with obstructive BPH. Initial study on experimental animal model].
    González Enguita C; Vela Navarrete R; Salcedo de Diego A; Pérez Martínez F; Ramírez Pérez del Yerro M; Cancho Gil MJ; Crespí Martínez F; Bravo Fernandez I; Cabrera Pérez J
    Actas Urol Esp; 2003 Oct; 27(9):684-91. PubMed ID: 14626677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of α1a and α1d-adrenoceptors in the prostate by administration of subtype selective α1-adrenoceptor antagonist tamsulosin in patients with benign prostatic hyperplasia.
    Kojima Y; Sasaki S; Kubota Y; Imura M; Oda N; Kiniwa M; Hayashi Y; Kohri K
    J Urol; 2011 Oct; 186(4):1530-6. PubMed ID: 21855934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.